Global Leading Market Research Publisher QYResearch announces the release of its latest report “Long-acting Beta-Agonists (LABAs) – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Long-acting Beta-Agonists (LABAs) market, including market size, share, demand, industry development status, and forecasts for the next few years.
Addressing core industry needs: COPD and asthma patients require daily bronchodilation for symptom control – but short-acting beta-agonists (SABAs) last only 4–6 hours. Long-acting beta-agonists (LABAs) solve this with 12–24 hour bronchodilation by continuously stimulating β2 receptors in airway smooth muscle, enabling once or twice daily maintenance therapy. Key drivers include fixed-dose combinations with ICS, GINA/GOLD guidelines, and generic entry.
The global market for Long-acting Beta-Agonists (LABAs) was estimated to be worth US$ 329 million in 2025 and is projected to reach US$ 448 million, growing at a CAGR of 4.6% from 2026 to 2032. In 2024, the average price is approximately US$ 23.7 per unit, with total sales reaching around 13.16 million units.
Long-acting Beta-Agonists (LABAs) are a class of inhaled bronchodilators commonly used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). They work by continuously stimulating β2 receptors in the airway smooth muscle, thereby maintaining prolonged bronchodilation. Compared to short-acting agents, LABAs provide extended relief, typically lasting more than 12 hours, making them well-suited for daily maintenance therapy and improving patients’ respiratory function and quality of life.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6098563/long-acting-beta-agonists–labas
Market Segmentation & Key Players
The Long-acting Beta-Agonists (LABAs) market is segmented as below:
Leading Suppliers: Boehringer Ingelheim, GlaxoSmithKline, LEK-AM, Novartis, Viatris, Zentiva, AstraZeneca, Chiesi Farmaceutici, Orion Corporation, Polpharma, Adamed Group, STADA Arzneimittel.
Segment by Type: Olodaterol | Salmeterol | Formoterol | Indacaterol | Others
Segment by Application: Hospital | Clinic | Others
Exclusive Industry Insights
Discrete DPI/MDI formulation: LABAs are formulated as micronized API (<5μm) blended with lactose (DPIs) or suspended in HFA propellant (MDIs). Receptor selectivity: high β2 vs. β1 affinity minimizes cardiac side effects.
Technical differentiation – LABA molecules:
| Molecule | Brand | Duration | Dosing | Onset |
|---|---|---|---|---|
| Salmeterol | Serevent | 12 hours | Twice daily | Slow (30 min) |
| Formoterol | Foradil | 12 hours | Twice daily | Fast (5 min) |
| Indacaterol | Onbrez | 24 hours | Once daily | Fast |
| Olodaterol | Striverdi | 24 hours | Once daily | Fast |
Recent 6-month data (Oct 2025 – Mar 2026):
- Formoterol largest segment (35% revenue), widely used in ICS/LABA combinations (Symbicort).
- Once-daily LABAs (indacaterol, olodaterol) fastest-growing (CAGR 5.5%).
- ICS/LABA fixed-dose combinations now represent 78% of LABA prescriptions (vs. LABA alone).
User case – Regional health system (US, 500,000 asthma patients): Formulary preference for generic formoterol (as part of ICS/LABA combination) reduced annual LABA spend by US$ 12M (28% savings). Exacerbation rates stable, adherence improved.
GINA/GOLD guideline recommendations:
| Condition | LABAs Role |
|---|---|
| Asthma (Step 3) | ICS + LABA (never LABA alone) |
| Asthma (Step 4-5) | ICS + LABA ± LAMA |
| COPD (Group B) | LABA or LAMA |
| COPD (Group E) | LABA + LAMA ± ICS |
Application insights: Hospital (45%) – specialty respiratory clinics, emergency follow-up. Clinic (48%) – primary care, pulmonology offices, maintenance prescriptions. Others (7%) – long-term care, home health.
Black box warning (FDA): LABAs increase risk of asthma-related death when used without ICS. All LABA products contraindicated as monotherapy in asthma.
Regional snapshot: North America leads with 52% revenue share (higher branded ICS/LABA prices). Europe holds 28% (generic penetration). Asia-Pacific fastest-growing (CAGR 5.8%), driven by COPD/asthma diagnosis.
Conclusion
The LABA market is mature but stable, driven by ICS/LABA combinations, once-daily formulations, and generic entry. Success depends on fixed-dose combination development, device differentiation, and safety communication. The projected US$ 448 million market by 2032 appears achievable.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
